Related Experiment Video
Updated: Feb 12, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Data Quality at the Indiana State Cancer Registry: An Evaluation of Timeliness by Cancer Type and Year
Abstract:
BACKGROUND: Central cancer registries collect tumor-related data to monitor incidence rates and support population- based research. One concern with using registry data for research is timeliness of reporting. Timeliness has been recognized as an important data characteristic by both the Centers for Disease Control and Prevention and the National Academy of Medicine. Yet, few studies in the United States have systematically measured timeliness. The purpose of this study is to evaluate timeliness in cancer-case reporting to a state population-based cancer registry. METHOD: Using the Indiana State Department of Health Cancer Registry, 66,395 breast, colorectal, and lung cancer diagnoses recorded during the years 2001–2009 were examined for timeliness. Timeliness was measured from the date the cancer was diagnosed to when the data were available at the state registry. Differences over time and among the 3 cancer types were examined. RESULT: Timeliness of reporting improved since 2003. Mean reporting time ranged from 426 days in 2003 to 253 days in 2009. We found significant difference in reporting time between the 3 cancer types. CONCLUSION: Timeliness of reporting has improved over time. Advances in health information technologies may have contributed to this improvement. However, achieving even more timely reporting for research purposes and care intervention may require moving away from traditional reporting methods.
Related Concept Videos
Data: Types and Distribution
Distributions in...
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

